Gelsana Therapeutics Inc.
Aurora, CO
Company facts
- SBA certifications
-
HUBZone Firm· Current
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 12635 E Montview Blvd #326, Aurora, CO 80045, USA
- Website
- gelsanatherapeutics.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $1,249,624 |
| FY2023 | $74,950 |
Contract awards
Grant awards
Similar vendors
About the company
Gelsana Therapeutics Inc. is a woman-owned small business and HUBZone certified corporation focused on developing advanced biomaterials and therapeutic technologies, specifically zwitterionic hydrogels for wound healing applications. The company specializes in innovative medical research and product development, targeting complex wound treatment challenges in both military and civilian healthcare contexts. Their core technological focus appears to be on creating specialized hydrogel systems that can deliver controlled therapeutic interventions, reduce inflammation, and accelerate wound healing processes.
Through federal contract awards, Gelsana Therapeutics Inc. has exclusively worked with the Department of the Air Force Materiel Command Research Laboratory under the Small Business Innovation Research (SBIR) Program. The company has received two prime contract awards, both centered on developing novel zwitterionic hydrogels for enhanced wound healing. The first contract (Phase I, awarded May 1, 2023, valued at $74,950) explored zwitterionic hydrogels for improved healing of burns, blast wounds, and chronic wounds. The subsequent contract (Phase II, awarded March 7, 2024, valued at $1,249,624) focused specifically on developing hydrogels to enhance wound healing in combat-related burn injuries. Both contracts were total small business set-aside awards, highlighting the company's commitment to innovative military healthcare solutions.
Regarding federal grant awards, Gelsana Therapeutics Inc. has received two project grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program. The first grant (R43DK134283, awarded April 24, 2023) focused on developing a topical drug delivery system as an anti-inflammatory and pro-angiogenic therapy for diabetic wound healing. The second grant (R43DK141293, awarded September 5, 2024, valued at $649,984) supports the development of Provasliex GelTM, a zwitterionic hydrogel designed to deliver controlled release of platelet-derived growth factor (PDGF) for managing diabetic foot ulcers. Both grants aim to address critical wound healing challenges, particularly in diabetic patients, by developing innovative hydrogel technologies that can reduce inflammation, promote vascularization, and accelerate wound healing.
Quick answers
Is Gelsana Therapeutics Inc. registered in SAM.gov?
Yes. Gelsana Therapeutics Inc.'s SAM.gov registration is active through April 28, 2027.
What is Gelsana Therapeutics Inc.'s CAGE code?
Gelsana Therapeutics Inc.'s CAGE code is 97R25, and its Unique Entity ID (UEI) is CPRMRH9NFTF5.
Which SBA certifications does Gelsana Therapeutics Inc. hold?
Gelsana Therapeutics Inc. holds HUBZone Firm certification from the SBA.
How much has Gelsana Therapeutics Inc. received in federal contracts?
Federal contracts obligated $1,324,574 to Gelsana Therapeutics Inc. in fiscal years 2023 through 2027.
What is Gelsana Therapeutics Inc.'s most recent federal award?
Gelsana Therapeutics Inc.'s most recent federal grant award is Advancing diabetic foot ulcer treatment with provasliex, a controlled pdgf release hydrogel for promoting… (R43DK141293), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 5, 2024.
On GovTribe
See Gelsana Therapeutics Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors